Nature Reviews Rheumatology

Article	Citations
Inflammatory arthritis affects men’s fertility	595
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	444
Bimekizumab effective across the axSpA spectrum	391
No benefit from adding MTX to ustekinumab	344
Low-dose rituximab can go even lower	324
Genome-wide mutagenesis reported in systemic sclerosis	299
Rheumatic diseases on the rise	282
A role for TGFβ and EBV in MIS-C pathogenesis	253
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	230
Targeting articular Mmp13 in OA	200
Biological and clinical roles of IL-18 in inflammatory diseases	191
New drug formulation reduces bone loss	182
FOXP3 splice variant is associated with autoimmune disease	173
Towards better management of sterile bone inflammation	168
Use of platelet-rich plasma for knee OA not supported by RCT results	164
MIS-C: myths have been debunked, but mysteries remain	163
Inflammation across tissues: can shared cell biology help design smarter trials?	151
Which NSAIDs are best for OA treatment?	150
Urchin-like nanoparticles for miRNA therapy of OA	143
2021 ACR guideline for JIA reflects changes in practice	142
The 2022 ACR vaccination guideline: a call-to-action	129
The value of comparative efficacy studies in informing rheumatology guidelines	119
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	119
To choose or not? The value of discrete-choice experiments in rheumatology	117
Down syndrome: insights into autoimmune mechanisms	116

Ageing stem cells hold the key to age-related bone degeneration	110
Appraising the evolving landscape of protease inhibition in osteoarthritis	106
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus	103
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	100
Co-trimoxazole reduces mortality in anti-MDA5-DM	95
Low-dose glucocorticoids benefit seniors with RA	93
Calprotectin tracks tocilizumab-treated RA	93
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	92
Wnt-induced IGF1 drives OA	92
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	89
Author Correction: Proposals for the rheumatological use of JAK inhibitors	88
Guiding ILD management in systemic autoimmune rheumatic diseases	87
A direct link between SARS-CoV-2 and bone loss	87
S100A4 inhibition targets fibrosis in SSc	85
Rheumatic diseases and metabolism: where centre and periphery meet	83
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	78
Fumarate drives interferon release in systemic sclerosis monocytes	78
Rheumatology in the digital health era: status quo and quo vadis?	77
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	76
Low back pain is a growing concern	74
sCD13 role in arthritis mediated via bradykinin receptor	74
Targeting the IVD clock to halt degeneration	73
Antibiotics keep rheumatic heart disease at bay	73
Erosive cargo from synovial fibroblasts	71
Which DMARD for ICI-associated arthritis?	70
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	69
ERAP1 and the return of the UPR in ankylosing spondylitis	68
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	68
PGE2 receptor antagonist has potential to treat osteoarthritis	66
Macrophage-coated nanocarriers for gouty arthritis	64
A path towards personalized medicine for autoinflammatory and related diseases	64
Insights into IVDD pathogenesis in 2024	62
CAR T cells induce drug-free SLE remission	62
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	61
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	60
Antibodies induce fibromyalgia symptoms	58
Blocking CDK7 attenuates inflammatory arthritis	57
PPIs linked to increased risk of knee replacement	56
TASL has a key role in SLE	55
RA risk from occupational inhalation	55
Two sides of management recommendations for psoriatic arthritis	54
Improving the design of RCTs in non-radiographic axial spondyloarthritis	52
All fibroblasts are equal, but some are more equal than others	50
Is air pollution linked with poor response to biologics?	49
Repolarizing macrophages using antagomirs	48
Profiling joint tissues at single-cell resolution: advances and insights	48
New refinements aim to optimize articular cartilage tissue engineering	48
Platelets as drivers of immunothrombosis in rheumatic diseases	48
A critical view of WHO guidelines on management of low back pain	46
A leading role for interferon as a treatment target in Sjögren syndrome	45

New hope for B cell-targeting therapy in pSS	45
New developments in electronic health record analysis	44
Piezo1 induces new bone formation in AS	43
Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis	43
Clarity for the language of race, ethnicity and genetic ancestry in rheumatology	42
Author Correction: Glycobiology of rheumatic diseases	42
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	42
AhR promotes suppressor cell function in Sjögren syndrome	39
Sex- and gender-based personalized medicine in rheumatology	39
APOE in fat pad and synovium contributes to knee OA	39
l-arginine inhibits arthritis and bone loss by reprogramming osteoclast metabolism	38
Pathogenic antibodies target stromal antigens in RA	38
Treg cell-inducing nanoparticles show promise for treating OA	38
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	36
CXCL5 effective in mouse model of SLE	36
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	35
Stromal cells implicated in RA genetic risk	35
Are DNA–HLA class II interactions the missing link in SLE?	35
Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases	35
Imaging for prediction of RA development	33
HLA autoimmunity risk alleles influence T cell receptor sequences	32
New OA risk factors and drug targets revealed	28
BiTE therapy for rheumatic diseases	27
Shifting the SLE management paradigm: challenges and implications	27
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade	26
FABP4 exacerbates RA	26
Location-specific treatment of chronic inflammatory joint disease	26
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13	26
Post-transcriptional checkpoints in autoimmunity	25
Critical appraisal of serum urate targets in the management of gout	25
Mechanisms and clinical implications of intervertebral disc calcification	25
COVID-19 linked to rise in anti-MDA5 autoimmunity	24
Guselkumab effective through 2 years in PsA trial	24
Detachment promotes RA synovial fibroblast survival and invasiveness	24
Multi-omics reveals distinct MPA subtypes	22
PLG nanoparticles target inflammatory monocytes in SSc	22
Adropin inhibits fibrosis in SSc	21
Notch signalling mediates OA pain in mice	20
Complement therapeutics are coming of age in rheumatology	19
State-of-the-art evidence in the treatment of systemic sclerosis	19
Busting the myth of methotrexate chronic hepatotoxicity	19
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	18
How the COVID-19 pandemic has affected rheumatology research	18
The potential contribution of in silico studies to improved treatment of osteoarthritis	18
Treatment of non-systemic juvenile idiopathic arthritis	17
Citrulline immunity in RA: CD8+ T cells enter the scene	16
Synovial fluid as a complex molecular pool contributing to knee osteoarthritis	16
Single-cell RNA sequencing sheds light on cell-type specific gene expression in immune cells	16
Joint distraction for osteoarthritis: clinical evidence and molecular mechanisms	16
Primary care rheumatology: towards sustainable development in health	15
No benefit to intensive urate lowering in gout	15
Lupus ABC spearheading a new era of collaboration to advance lupus drug development	15
Update on the pathophysiology and treatment of primary Sjögren syndrome	15
The immune health metric as an indicator of health and disease	15
Undiagnosed axSpA is prevalent in IBD	15
UNC93B1 variants promote SLE via TLR activation	15
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	15
Shedding light onto the immunometabolic effects of glucocorticoids	15
Bone-modifying drugs slow OA progression	15
Interleukin-2 and regulatory T cells in rheumatic diseases	14
Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications	14
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	14
The PU.1– IL-9 axis in TH9 cells promotes RA	14
Glycosylation switch in synovial fibroblasts promotes ECM degradation	13
Combination therapy for Behçet uveitis	13
More than a leaky gut: how gut priming shapes arthritis	12
T cell differentiation in Sjögren syndrome is regulated by TOX	12
The role of the immune system in osteoarthritis: mechanisms, challenges and future directions	12
Reversal of inflammatory priming prevents arthritic flares	12
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?	12
Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy	12
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk	12
New guide calls for interdisciplinary approach to TMJ arthritis symptoms	12
Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition	11
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy	11
Paediatric glucocorticoid toxicity index: new possibilities in assessment	11
Disease stratification in GCA and PMR: state of the art and future perspectives	11
Advances in the calculation of minimal important change estimates for patient-reported outcome measures	11
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies	11
PPM1A: TGFβ regulator and therapeutic target in OA	10

Evidence-Based Guideline for the management of osteoporosis in men	10
Pregnancy outcomes improving in axSpA	10
Novel TLR7 variant causes lupus	10
Real-world data provide insights into PsA treatment patterns	9
Imaging in inflammatory arthritis: progress towards precision medicine	9
A new immunometabolic perspective of intervertebral disc degeneration	9
Age-related mechanisms in the context of rheumatic disease	9
Treat-to-target or treat-to-dissolve strategy to improve gout treatment	9
Kindlin-2 reduces IVD inflammation	9
CD38hiCD8+ T cells characterize ICI-mediated arthritis	9
Macrophages hit a nerve in painful joint venture	9
When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy	9
The apprehension of seronegative rheumatoid arthritis	9
PJP prophylaxis with rituximab	8
Gut T cells help mediate fracture healing	8
Benralizumab noninferior to mepolizumab for EGPA	8
Author Correction: New genes, pathways and therapeutic targets in autoinflammatory diseases	8
Annexin A1 could help prevent periprosthetic bone loss	8
TGFβ priming promotes TNF-induced bone erosion: a promising new target in RA?	7
Immunogenic Xist ribonucleoproteins drive sex-biased autoimmunity	7
New treatments for amyloidosis	7
New guideline for integrative approaches to RA management	7
GCA management guidelines — vive la différence?	7
Knee OA progression risk with steroids or HA	7
Optimizing methotrexate withdrawal during COVID vaccination	7
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout	6
IL-17A and IL-17F in tissue homeostasis, inflammation and regeneration	6
Relapsing polychondritis: clinical updates and new differential diagnoses	6
ZEB2 promotes formation of age-related B cells	6
HLA-B27 and spondyloarthritis: at the crossroads of innate and adaptive immunity	6
Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone	5
ETS1 implicated in polarization of tissue-destructive fibroblasts	5
High risk of autoimmune diseases after COVID-19	5
New screening tool developed to aid diagnosis of axial PsA	5
Mechanism of B cell survival in lupus nephritis	5
Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis	5
Collagen-binding antibody prevents arthritis	5
Pregnancy outcomes in SLE have not improved	5
Lupus nephritis-related chronic kidney disease	5
Sarcoidosis: can tofacitinib slay the dragon?	4
How muscle influences bone health	4
Does psoriasis treatment affect PsA development?	4
Understanding synovial cell diversity in post-traumatic OA	4
Cardio-rheumatology: it’s time to collaborate	4
JAK inhibitors improve RA pain	4
Reply to: Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups	4
The role of mitochondria in rheumatic diseases	4
Integrin signalling in joint development, homeostasis and osteoarthritis	4
IRAK4 inhibitor attenuates inflammation	4
The peculiar features, diversity and impact of citrulline-reactive autoantibodies	4
Limitations of the updated EULAR recommendations for osteoarthritis	4
SLE risk variant regulates IRF8 expression	4
Clonal dominance: mutations in VEXAS syndrome take advantage of inflammation	4
Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress	4
A basket genetic trial of the vasculitides	3
A roadmap for delivering a human musculoskeletal cell atlas	3
Treating inflammatory arthritis in individuals with concomitant cancer	3
A subset of ITGA5+ synovial fibroblasts alter the inflammatory niche in RA	3
New evidence for the ‘cusp theory’ to explain HLA associations in SLE	3
Pentose phosphate pathway metabolite restores T cell balance in SLE	3
Joint-on-chip platforms: entering a new era of in vitro models for arthritis	3
Reply to: Hypothetical model ignores many important pathophysiologic mechanisms in fibromyalgia	3
T cells in Sjögren disease	3
Targeting IL-23 for axial disease in PsA	3
Hypoxia-modifying hydrogel supports stem cells for joint repair	3
NK cells induce a pro-inflammatory phenotype in RA synovial fibroblasts	3
Metabolic reinvigoration of immune tolerance	3
Breaking research silos to achieve equitable precision medicine in rheumatology	3
Nasal chondrocytes enable cartilage repair in OA joints	3
VEXAS syndrome more common than originally thought?	3
PR3 triggers granuloma formation in GPA	3
Targeting UHRF1 in RA	3
A comprehensive guide for managing the reproductive health of patients with vasculitis	3
Is X chromosome inactivation a cause or effect of SLE?	3
Sex and gender matter for TNF inhibitor therapy in RA	3
Understanding rheumatic disease through continuous cell state analysis	3
Joint location matters for TNF inhibitor treatment in PsA	3
Fibroblasts in immune responses, inflammatory diseases and therapeutic implications	3
The therapeutic potential of immunoengineering for systemic autoimmunity	3
Publisher Correction: IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	3
Integrin-mediated ILC2 adhesion protects against lupus nephritis	3
Targeted NOD2 sequencing uncovers JIA misdiagnosis	2
Restoring cartilage lubrication to heal post-traumatic OA	2
Antigen-specific immunotherapies for autoimmune disease	2
Rethinking antiphospholipid syndrome to guide future management and research	2
Advancements and challenges in CAR T cell therapy in autoimmune diseases	2
‘Hyalinization’ for cartilage regeneration	2
SARS-CoV-2 vaccine safe for young patients	2
Treatment of lupus nephritis: consensus, evidence and perspectives	2
Helicobacter pylori-induced citrullination linked to RA exacerbation	2
Platelets promote cardiovascular complications in Kawasaki disease	2
Non-depleting anti-CD19 B cell inhibition	2
Promise and challenge of systemic sclerosis therapies	2
CXCL7 promotes bone erosion in RA	2
Nanoparticle-based pazopanib shows promise in OA	2